Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes
Open Access
- 1 December 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 17 (12), 3472-3481
- https://doi.org/10.1681/asn.2006060560
Abstract
For assessment of the independent renoprotective effect of BP control and angiotensin-converting enzyme inhibitor (ACEi) therapy, the relationships of baseline BP, BP reduction, and follow-up BP with the incidence of persistent microalbuminuria were evaluated in 1204 hypertensive patients who had type 2 diabetes and normoalbuminuria and were included in the BErgamo Nephrologic Diabetic Complications Trial (BENEDICT) study and were randomly assigned to 3.6 yr of treatment with the ACEi trandolapril (2 mg/d), the nondihydropyridine calcium channel blocker (ndCCB) verapamil SR (240 mg/d), their fixed combination Veratran (trandolapril 2 mg/d plus verapamil SR 180 mg/d), or placebo, plus other antihypertensive medications targeted at systolic/diastolic BP versus baseline—but not baseline BP—independently predicted (P < 0.001) the risk for microalbuminuria. In patients with follow-up BP above medians, ACEi significantly reduced the risk for microalbuminuria to levels that were observed among patients with BP below medians, regardless of ACEi treatment. The same trend was observed among patients with BP reductions below medians. ndCCB therapy did not independently affect microalbuminuria. Patients who were on Veratran had lower BP and less frequently received diuretics, β blockers, or dihydropyridine dCCB. In hypertensive, normoalbuminuric patients with type 2 diabetes, BP reduction and ACEi therapy both independently may prevent microalbuminuria. ACEi therapy is particularly effective when BP is poorly controlled, whereas ndCCB therapy is ineffective at any level of achieved BP. As compared with trandolapril, Veratran may help with achievement of target BP with less need for concomitant antihypertensive medications.Keywords
This publication has 27 references indexed in Scilit:
- Time to abandon microalbuminuria?Kidney International, 2006
- Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy TrialJournal of the American Society of Nephrology, 2005
- Antihypertensive Agents for Primary Prevention of Diabetic NephropathyJournal of the American Society of Nephrology, 2005
- Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy TrialJournal of the American Society of Nephrology, 2005
- Hypertension Management in Adults With DiabetesDiabetes Care, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Nifedipine versus fosinopril in uninephrectomized diabetic ratsKidney International, 1992
- Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.JCI Insight, 1986
- Glomerular hemodynamics in experimental diabetes mellitusKidney International, 1981
- Progression of Nephropathy in Long-Term Diabetics with Proteinuria and Effect of Initial Anti-Hypertensive TreatmentScandinavian Journal of Clinical and Laboratory Investigation, 1976